<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137813">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843881</url>
  </required_header>
  <id_info>
    <org_study_id>11-007667</org_study_id>
    <secondary_id>R01DK082396</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01843881</nct_id>
  </id_info>
  <brief_title>The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass</brief_title>
  <official_title>The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Vella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being undertaken to understand how the Roux-en-Y Gastric Bypass procedure can
      affect insulin secretion after meals. The hypothesis of this study is the Disposition Index
      is decreased in subjects who had previously undergone Roux-en-Y Gastric Bypass by
      glucagon-like peptide-1 (GLP-1) receptor blockade.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in Total Disposition Index from Study 1 (Exendin 9,39) to Study 2 (saline)</measure>
    <time_frame>Day 1, Day 2 (approximately 2 weeks after day 1)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total disposition index equals the product of insulin secretion and insulin sensitivity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Exendin 9, 39</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A saline infusion will be administered in either first intervention period or second intervention period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin 9, 39</intervention_name>
    <description>Exendin 9,39 is a competitive antagonist of endogenous GLP-1.</description>
    <arm_group_label>Exendin 9, 39</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A saline infusion will be given to match the study drug infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Roux-en-Y Gastric Bypass (RYGB)Subjects:

          -  Subjects who have undergone RYGB

        Inclusion Criteria Healthy Subjects:

          -  Must match RYGB subjects in age, weight, and gender

          -  Subjects will be without active systemic illness

        Exclusion Criteria all Subjects:

          -  Subjects &lt;20 years old and &gt;70 years old

          -  For Female Subjects: positive pregnancy text at the time of enrollment or study

          -  Subjects with functional or organic bowel symptoms.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>April 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Consultant, Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Gastric Bypass</keyword>
  <keyword>bariatric surgery</keyword>
  <keyword>carbohydrate metabolism</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
